beta
Trial Radar AI
Clinical Trial NCT07491159 for Colorectal Cancer is active, not recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here.
One study matched filter criteria
Card View
Back to Search

Fruquintinib Plus Checkpoint Inhibitor Combined or Sequential TAS-102 in Colorectal Cancer Patients Who Progressed on Second-line Standard Therapy: a Prospective, Multi-cohort, Single-centered, Phase Ib/II Study Phase 1, Phase 2 106 Immunotherapy Targeted Therapy Combination Therapy Overall Survival

Active, not recruiting
Clinical Trial NCT07491159 is designed to study Treatment for Colorectal Cancer. It is a Phase 1 Phase 2 interventional study that is active, not recruiting, having started on 1 July 2023, with plans to enroll 106 participants. Led by Tianjin Medical University Cancer Institute and Hospital, it is expected to complete by 30 December 2026. The latest data from ClinicalTrials.gov was last updated on 24 March 2026.
Brief Summary
Colorectal cancer (CRC) is the fourth leading cause of cancer death worldwide, claiming approximately 900,000 lives annually. In China, CRC has become one of the top three most common cancers, with about 555,000 new cases and 286,000 deaths reported in 2020.

For patients with advanced metastatic colorectal cancer (mCRC), chemotherapy remains the main treatment approach. While first and second-line treatments have im...

Show More
Official Title

Fruquintinib Plus Checkpoint Inhibitor Combined or Sequential Trifluridine/Tipiracil(TAS-102) Based Regimen in Colorectal Cancer Patients Who Progressed on Second-line Standard Therapy: a Prospective, Multi-cohort, Single-centered, Phase Ib/II Study

Conditions
Colorectal Cancer
Other Study IDs
  • CRC later-line
NCT ID Number
NCT07491159
Start Date (Actual)
2023-07-01
Last Update Posted
2026-03-24
Completion Date (Estimated)
2026-12-30
Enrollment (Estimated)
106
Study Type
Interventional
PHASE
Phase 1
Phase 2
Status
Active, not recruiting
Keywords
fruquintinib
Trifluridine/tipiracil
Microsatellite Stable
metastatic colorectal cancer
Primary Purpose
Treatment
Design Allocation
Non-Randomized
Interventional Model
Parallel
Masking
None (Open Label)
Arms / Interventions
Participant Group/ArmIntervention/Treatment
ExperimentalFruquintinib plus immunocheckpoint inhibitor plus trifluridine/tipiracil
Fruquintinib plus immunocheckpoint inhibitor plus trifluridine/tipiracil
Fruquintinib plus immunocheckpoint inhibitor plus trifluridine/tipiracil
Fruquintinib plus immunocheckpoint inhibitor plus trifluridine/tipiracil
ExperimentalFruquintinib plus immunocheckpoint inhibitor followed by trifluridine/tipiracil plus bevacizumab
Fruquintinib plus immunocheckpoint inhibitor followed by trifluridine/tipiracil plus bevacizumab
Fruquintinib plus immunocheckpoint inhibitor followed by trifluridine/tipiracil plus bevacizumab
Fruquintinib plus immunocheckpoint inhibitor followed by trifluridine/tipiracil plus bevacizumab
Primary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
RP2D
Recommended phase 2 dose
From enrollment to the end of treatment at 4 week
Overall Survival (OS)
Time from randomization/enrollment to death from any cause
Up to 36 months
Secondary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
Progress-free Survival (PFS)
Time from randomization/enrollment to first documented disease progression (per RECIST v1.1) or death from any cause, whichever occurs first
Assessed every 8 weeks, up to 12 months
Objective Response Rate (ORR)
The proportion of patients who achieve a confirmed complete response (CR) or partial response (PR) as their best overall response, as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
Tumor assessments performed at baseline, then every 8 weeks (±7 days) from the date of first dose until radiographic disease progression or death, assessed up to approximately 12 months
Duration of Response (DoR)
Time from first documented response (CR/PR) to disease progression or death
Up to 12 months
Incidence of AEs
Number and percentage of participants experiencing adverse events graded by NCI-CTCAE v5.0
by NCI-CTCAE v5.0. From first dose up to 30 days after last dose
Incidence of SAEs
Number and percentage of participants experiencing serious adverse events
From informed consent up to 30 days after last dose
Number of participants with Laboratory abnormalities
Incidence of clinically significant laboratory parameter changes per NCI-CTCAE v5.0
From baseline up to 30 days after last dose
Participation Assistant
Eligibility Criteria

Eligible Ages
Adult, Older Adult
Minimum Age
18 Years
Eligible Sexes
All
  • Fully informed about this study and voluntarily signed the informed consent form;
  • Age 18-75 years (inclusive);
  • Histologically confirmed unresectable metastatic colorectal cancer;
  • Confirmed pMMR (proficient mismatch repair) status without protein loss, as determined by:PCR testing showing microsatellite stable (MSS) or low microsatellite instability (MSI-L), OR Immunohistochemistry (IHC) demonstrating intact DNA mismatch repair (MMR) protein expression (including MLH1, MSH2, MSH6, and PMS2);
  • Failed or intolerant to two prior lines of standard systemic therapy for metastatic colorectal cancer;
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-2;
  • Body Mass Index (BMI) ≥18 kg/m²;
  • Life expectancy ≥3 months;
  • Adequate organ function as defined below (no blood components or growth factors allowed within 14 days prior to enrollment):
  • Hematologic Function:

Absolute neutrophil count (ANC) ≥1.5×10⁹/L; White blood cell count (WBC) ≥4.0×10⁹/L; Platelet count ≥100×10⁹/L; Hemoglobin ≥90 g/L; -Hepatic Function: Total bilirubin (TBIL) ≤1.5× upper limit of normal (ULN); Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤5×ULN;

-Renal Function: Blood urea nitrogen (BUN) and creatinine (Cr) ≤1.5×ULN; Creatinine clearance (CCr) ≥50 mL/min;

-Cardiac Function: Left ventricular ejection fraction (LVEF) ≥50%; QT interval corrected by Fridericia's formula (QTcF) <470 ms;

-Coagulation Function: International normalized ratio (INR) ≤1.5×ULN; Activated partial thromboplastin time (APTT) ≤1.5×ULN;

  • Women of childbearing potential must use effective contraception;
  • Good compliance and willing to cooperate with follow-up visits.

  • Unable to comply with the study protocol or study procedures;
  • Prior treatment with TAS-102 (trifluridine/tipiracil);
  • Prior treatment with VEGFR inhibitors;
  • Prior treatment with immune checkpoint inhibitors;
  • Concurrent use of any other investigational drugs, or participation in another clinical trial with investigational drug treatment within 4 weeks prior to enrollment;
  • Vaccination with inactivated vaccines within 4 weeks prior to enrollment or planned vaccination during the study period;
  • Major surgery, severe traumatic injury, fracture, or ulcer within 4 weeks prior to enrollment;
  • Blood transfusion, blood products, or hematopoietic factors (such as albumin, granulocyte colony-stimulating factor \[G-CSF\], etc.) within 28 days prior to enrollment;
  • Alcohol or drug abuse within 4 weeks prior to enrollment;
  • Any factors affecting oral drug administration;
  • Concurrent presence of any of the following conditions:
  • Uncontrolled hypertension, coronary artery disease, arrhythmia, or heart failure;
  • Uncontrolled severe concurrent infection resulting in disability;
  • Proteinuria ≥2+ (1.0 g/24 h);
  • Evidence or history of bleeding tendency within 2 months prior to enrollment, regardless of severity;
  • Arterial/venous thromboembolic events within 12 months prior to first treatment, such as cerebrovascular accident (including transient ischemic attack), etc.;
  • Acute myocardial infarction, acute coronary syndrome, or coronary artery bypass grafting (CABG) within 6 months prior to first treatment;
  • Fracture or long-term unhealed wounds;
  • Coagulation dysfunction, bleeding tendency, or currently receiving anticoagulant therapy;
  • Evidence of central nervous system (CNS) metastasis, or accompanied by severe malignant pleural effusion or ascites;
  • Other malignancies within 5 years prior to enrollment, except for basal cell or squamous cell carcinoma of the skin after curative surgery, or carcinoma in situ of the cervix;
  • Active autoimmune disease or history of autoimmune disease within 4 weeks prior to enrollment;
  • Prior allogeneic bone marrow transplantation or organ transplantation;
  • Known hypersensitivity to study drugs or any of their excipients;
  • Unresolved toxicities greater than CTCAE v5.0 Grade 1 from prior anti-cancer therapy, excluding alopecia, lymphopenia, and oxaliplatin-induced neurotoxicity ≤Grade 2;
  • Any other disease, clinically significant metabolic abnormality, physical examination abnormality, or laboratory abnormality that, in the investigator's judgment, provides reasonable suspicion that the patient has a condition unsuitable for the use of the study drug (e.g., epileptic seizures requiring treatment), or that would affect the interpretation of study results, or would place the patient at high risk;
  • Pregnant or breastfeeding women;
  • Any patient deemed unsuitable for enrollment in this study by the investigator.
Tianjin Medical University Cancer Institute and Hospital logoTianjin Medical University Cancer Institute and Hospital378 active studies to explore
No contact data.
1 Study Locations in 1 Countries

Tianjin Municipality

Tianjin Cancer Hospital, Tianjin, Tianjin Municipality, 300202, China